Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Contributed by: Business Wire

Logo

Tags

Cardiology

Biotechnology

Pharmaceutical

Finance

Health

FDA

Professional Services

Clinical Trials

More Like This

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Bayer receives MHRA authorisation for Beyonttra® ▼ (acoramidis) as a new treatment of transthyretin amyloidosis in adult patients with cardiomyopathy